Drug Profile
Research programme: glycogen synthase kinase-3 inhibitors - Roche
Alternative Names: 3544; Compound 3544; GSK-3 inhibitors - RocheLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Roche
- Class Small molecules
- Mechanism of Action Glycogen synthase kinase 3 inhibitors; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis in USA (PO)
- 02 Oct 2006 Preclinical trials in Osteoporosis in USA (PO)